Becton, Dickinson and Company (NYSE:BDX) is scheduled to be issuing its quarterly earnings data before the market opens on Wednesday, November 1st. Analysts expect the company to announce earnings of $2.37 per share for the quarter. Becton, Dickinson and has set its FY17 guidance at $9.42-9.47 EPS.
Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, topping analysts’ consensus estimates of $2.44 by $0.02. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The company had revenue of $3.04 billion during the quarter, compared to analyst estimates of $3.06 billion. During the same quarter last year, the firm posted $2.35 earnings per share. The firm’s revenue was down 5.1% on a year-over-year basis. On average, analysts expect Becton, Dickinson and to post $9.46 EPS for the current fiscal year and $10.45 EPS for the next fiscal year.
Shares of Becton, Dickinson and Company (NYSE BDX) opened at 208.65 on Tuesday. The company has a 50-day moving average price of $199.98 and a 200-day moving average price of $195.13. The stock has a market cap of $47.48 billion, a price-to-earnings ratio of 60.43 and a beta of 1.05. Becton, Dickinson and Company has a 52 week low of $161.29 and a 52 week high of $214.72.
In other Becton, Dickinson and news, insider Thomas E. Polen, Jr. sold 5,971 shares of the company’s stock in a transaction on Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total value of $1,178,735.11. Following the completion of the sale, the insider now directly owns 12,861 shares in the company, valued at approximately $2,538,890.01. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Linda M. Tharby sold 4,695 shares of the company’s stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $200.48, for a total value of $941,253.60. Following the completion of the sale, the executive vice president now owns 18,670 shares of the company’s stock, valued at $3,742,961.60. The disclosure for this sale can be found here. Insiders sold a total of 75,904 shares of company stock valued at $15,242,688 over the last quarter. Company insiders own 1.40% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Becton, Dickinson and Company (BDX) Scheduled to Post Quarterly Earnings on Wednesday” was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.com-unik.info/2017/10/31/becton-dickinson-and-company-bdx-scheduled-to-post-quarterly-earnings-on-wednesday.html.
Several brokerages have commented on BDX. Barclays PLC reaffirmed an “equal weight” rating and issued a $210.00 price objective (up previously from $205.00) on shares of Becton, Dickinson and in a research report on Thursday, August 10th. BidaskClub downgraded Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Zacks Investment Research raised Becton, Dickinson and from a “sell” rating to a “hold” rating in a research report on Friday, October 20th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $213.00 price objective on shares of Becton, Dickinson and in a research report on Tuesday, September 12th. Finally, Stifel Nicolaus reaffirmed a “buy” rating on shares of Becton, Dickinson and in a research report on Wednesday, August 9th. Five investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $205.14.
About Becton, Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
What are top analysts saying about Becton Dickinson and Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Becton Dickinson and Company and related companies.